Found: 10
Select item for more details and to access through your institution.
Comparation of fixed‐ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon‐like peptide‐1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta‐analysis.
- Published in:
- Journal of Evidence-Based Medicine, 2024, v. 17, n. 2, p. 370, doi. 10.1111/jebm.12620
- By:
- Publication type:
- Article
OP13 Cost-Effectiveness Analysis Of Sintilimab Plus Chemotherapy For The First-Line Treatment Of Non-Squamous Non-Small Cell Lung Cancer: Societal Perspective.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, p. S4, doi. 10.1017/S0266462323000624
- By:
- Publication type:
- Article
OP11 Cost-Effectiveness Of Atezolizumab Plus Chemotherapy As A First-Line Treatment For Metastatic Non-Squamous Non-Small Cell Lung Cancer.
- Published in:
- 2023
- By:
- Publication type:
- Abstract
Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 10, p. 3905, doi. 10.1007/s12325-024-02863-4
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 4, p. 1436, doi. 10.1007/s12325-024-02808-x
- By:
- Publication type:
- Article
Correction to: Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 6, p. 2971, doi. 10.1007/s12325-022-02161-x
- By:
- Publication type:
- Article
Treatment and economic burden of mucormycosis in China: Case report review and burden estimation.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 7, p. 905, doi. 10.1111/jcpt.13643
- By:
- Publication type:
- Article
Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
- Published in:
- Journal of Neuro-Oncology, 2024, v. 168, n. 2, p. 259, doi. 10.1007/s11060-024-04662-x
- By:
- Publication type:
- Article
Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 10, p. 1, doi. 10.1002/cam4.7243
- By:
- Publication type:
- Article